Business
ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update
LYON, France, May 12, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2026 and provides a business update.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/5fdb253823675c87afb009f07453204a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NJMtQZybP7Ocq.9liIdWtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/5fdb253823675c87afb009f07453204a","width":960,"height":388},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/gvkWIUgd6VJbgisATgniug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI1OQ--/https://media.zenfs.com/en/business-wire.com/5fdb253823675c87afb009f07453204a","width":640,"height":259},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EYBV1x6Ax9BCqORuSPlzqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA-/https://media.zenfs.com/en/business-wire.com/5fdb253823675c87afb009f07453204a","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €12.0 million as of March 31, 2026","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Shareholder loan agreement signed with Vester Finance on April 21, 2026, securing a cash runway until the beginning of Q2 2027","length":126,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"BioChaperone®: strategic priority given to BioChaperone® as feasibility studies have yielded positive results, and a new study has been initiated","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AdoShell®: suspension of the submission of the clinical trial application originally scheduled for Q3 2026","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Board of Directors: Stéphane Boissel appointed as Chairman and Jacky Vonderscher co-opted as Director","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":529,"olType":false},{"type":"text","content":"LYON, France, May 12, 2026--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2026 and...